Anupam Rasayan India Ltd

- The company has recently raised Rs. 180 crores through equity shares and Rs. 370 crores through warrants to promoters and institutional investors, with Rs. 272 crores already received. - Out of the funds raised, Rs. 198 crores have been utilized for debt repayment so far. - The management has a strong focus on deleveraging and aims to become a long-term debt-free company within the next 18 months. - Currently, they do not anticipate needing significant external capital for growth and are actively repaying debts. - There is no mention of any planned new fundraising through debt or equity in the near future. - Maintenance and remaining CAPEX of Rs. 289 crores (out of a total Rs. 670 crores planned) will be funded from existing cash and resources, with Rs. 577 crores in cash available as of December 31, 2023.

- The company has a planned CAPEX of Rs. 670 crores, with Rs. 381 crores incurred in the first 9 months of FY '24. - The remaining CAPEX is expected to be completed in the next two quarters, likely by the first half of FY '25. - Post this large CAPEX, future expenditure will primarily be maintenance CAPEX with no new major CAPEX planned currently. - The completed CAPEX will support revenue growth for the next 2-3 years, with capacity deemed sufficient for current and near-future demand. - Investment in a 9.6 MW hybrid power plant (5.6 MW wind, 4 MW solar) with Rs. 59 crores planned, aimed at reducing energy costs by approximately Rs. 15 crores annually. - Strategic focus includes strengthening capacities, especially in fluorination, and expanding into pharma, polymer, and agro segments. - The company is focused on deleveraging, aiming to become long-term debt-free over the next 18 months.

- Growth expected to pick up strongly from FY 2025 onwards after a subdued FY 2024 due to inventory realignment by customers. - LOIs (Letters of Intent) and long-term contracts show robust customer engagement and are expected to contribute significantly to revenue growth in FY 2025 and FY 2026. - New product launches, especially in pharma, polymers, and fluorination segments, will drive meaningful incremental volumes and revenue. - Existing capacity can support revenue growth up to Rs. 1,700-1,800 crores; recent and upcoming CAPEX of Rs. 670 crores to be completed by H1 FY 2025 will enable servicing growth for the next 2-3 years. - Pharma expected to contribute double-digit growth; polymer and specialty chemicals to contribute 15-20% revenue share in FY 2025. - Growth expected from both historical products (providing stability) and new molecules commercialized in the past two years (currently in teens percentage revenue contribution and rising). - Demand momentum projected to resume and sustain growth beyond FY 2025.

- Growth expected to pick up from FY 2025, driven by new product launches and LOI commercialization (Page 16). - Robust demand growth anticipated for next 2-3 years post FY 2025 due to order pipeline and new products (Page 12). - Historical products provide revenue stability; pharma and polymer sectors expected to contribute meaningfully to growth in FY 25 and FY 26 (Page 7). - EBITDA margins remain stable around 27-30%, with the business model focusing on EBITDA rather than gross margin (Page 16, Page 6). - Interest savings of approximately Rs. 24 crores expected in FY 2025 due to debt repayment (Page 8). - Capacity expansions through Rs. 670 crore CAPEX planned to complete by H1 FY 2025, supporting growth and ensuring no capacity constraints (Page 16). - Working capital optimization is a management focus to support cash flow and growth (Page 12).

- The company has signed several Letters of Intent (LOIs) and contracts with robust customer engagement and strong interest for long-term demand. - Most of the LOIs are expected to commercialize within the next two years (2024–2026). - Existing capacities can support revenue of Rs. 1,700-1,800 crores; no expected capacity constraints. - New CAPEX of Rs. 670 crores is underway, expected to complete by first half of FY '25, boosting capacity for the next 2-3 years. - Demand for contracted business has been subdued in the short term due to inventory de-stocking and client realignment. - Recovery and growth in orders are expected from Q1 FY '25, with FY '25 projected as a strong growth year. - Pharma and polymer portfolios, supported by new molecules, should contribute significantly to order book growth. - Contracts typically include a minimum guaranteed offtake with potential upsides, reducing risk of volume loss.